Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment

Boyrie, Sabrina; Fauquet, I.; Rives, M.; Génébès, C.; Delord, Jean‐Pierre

doi:10.1186/2193-1801-2-679

Cited by 8 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, cases showing distant metastases such as lung and bone metastases have been reported (3). While various chemotherapies are used for advanced SGCs and their efficacy may be dependent on histological type, overall, the results are unsatisfactory and there have been no reports of significant tumor responses to systemic chemotherapies in advanced cystadenocarcinoma (1,(11)(12)(13). Programmed death ligand 1 (PD-L1) expression in SGC tumor cells is frequently observed, indicating that it may play an important role in the immune tolerance and progression of SGC (14).…”

Section: Discussionmentioning

confidence: 99%

Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy

et al. 2021

View full text Add to dashboard Cite

Although cystadenocarcinoma is classified as a low-grade histological subtype of salivary gland carcinoma (SGC), recurrence and metastases sometimes develop. However, standard treatments for advanced cases have not yet been established. Here, we present a case of unresectable local recurrence and cervical lymph node metastases of cystadenocarcinoma of the parotid gland with multiple lung nodules, all of which showed complete response with only a single course of combined nivolumab and ipilimumab therapy. The patient's medical history of metastatic melanoma roused our suspicions that the multiple lung nodules were cystadenocarcinoma metastases or malignant melanoma. Combination therapy was used based on our suspected diagnosis of lung metastases of melanoma although histological examination of the lung nodules could not be performed. While various chemotherapies are used for advanced SGCs including cystadenocarcinoma, overall, the results are unsatisfactory. In contrast, there have not yet been any reports of advanced cystadenocarcinoma of the salivary gland treated with immune checkpoint inhibitors (ICIs). Given that, in our case, a single course of combined ICI therapy induced a complete response in the unresectable and lymph node metastases from the cystadenocarcinoma and the multiple lung nodules, ICIs, including combined therapy, could be a promising treatment for advanced cystadenocarcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A prior case report described the use of vemurafenib alone after disease progression occurred during treatment with combination 5-fluorouracil and cisplatin in a patient with BRAF V600E–mutated parotid cystadenocarcinoma. 25 Another case reported on a series of patients with SDC whose tumors were analyzed using targeted mutational analysis, and described in detail one patient who harbored a BRAF V600E mutation. 26 That patient experienced disease progression after definitive concurrent chemoradiotherapy with weekly carboplatin and paclitaxel, and again after salvage chemotherapy with cyclophosphamide and doxorubicin.…”

Section: Discussionmentioning

confidence: 99%

First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition

Lin¹,

Nabell²,

Spencer³

et al. 2018

J Natl Compr Canc Netw

View full text Add to dashboard Cite

Salivary duct carcinoma (SDC) is a rare and aggressive malignancy for which limited data exist to guide treatment decisions. With the advent of advanced molecular testing and tumor genomic profiling, clinicians now have the ability to identify potential therapeutic targets in difficult-to-treat cancers such as SDC. This report presents a male patient with widely metastatic SDC found on targeted next-generation sequencing to have a BRAF p.V600E mutation. He experienced a prolonged and robust response to first-line systemic chemotherapy with dabrafenib and trametinib. During his response interval, new data emerged to justify subsequent treatment with both an immune checkpoint inhibitor and androgen blockade after his disease progressed. To our knowledge, this is the first report of frontline BRAF-directed therapy eliciting a response in metastatic SDC.

show abstract

“…To date, the published literature contains only a few reports regarding genetic alteration of RAF mutations in salivary gland tumors . Nardi et al , using SNaPshot molecular profiling, identified a BRAF mutation in 7% (two of 27) of cases of salivary duct carcinoma (SDC).…”

Section: Discussionmentioning

confidence: 99%

Assessment of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in benign and malignant salivary gland neoplasms

Bodnar

Burduk

Antosik

et al. 2016

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment

Cited by 8 publications

References 9 publications

Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy

Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy

First-Line Treatment of Widely Metastatic BRAF-Mutated Salivary Duct Carcinoma With Combined BRAF and MEK Inhibition

Assessment of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in benign and malignant salivary gland neoplasms

Contact Info

Product

Resources

About